Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.50 |
| ▸ | TUBB | P07437 | 1/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933573 | 1.00 | ABCG2 (0.65) | ABCG2NPC1RAB9ACYP1A1CYP1B1 | |
| SCHEMBL4939430 | 0.93 | ABCG2 (0.65) | ABCG2NPC1RAB9ACYP1A1CYP1B1 | |
| SCHEMBL4933533 | 0.93 | ABCG2 (0.65) | ABCG2NPC1RAB9ACYP1A1CYP1B1 | |
| SCHEMBL13424781 | 0.90 | ABCG2 (0.62) | ABCG2TP53SAE1UBA2 | |
| SCHEMBL10852243 | 0.89 | ABCG2 (0.60) | ABCG2TP53SAE1UBA2 | |
| SCHEMBL10852248 | 0.89 | ABCG2 (0.60) | ABCG2TP53SAE1UBA2 | |
| SCHEMBL417823 | 0.87 | ABCG2 (0.65) | ABCG2NPC1RAB9ACYP1A1CYP1B1 | |
| SCHEMBL417824 | 0.87 | ABCG2 (0.65) | ABCG2NPC1RAB9ACYP1A1CYP1B1 | |
| SCHEMBL13021662 | 0.87 | ABCG2 (0.50) | ABCG2NPC1RAB9AKMT2AMAPT | |
| SCHEMBL874615 | 0.86 | MAPT (0.66) | ABCG2NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| EP-1783115-B1 | ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | INST MATERIA MEDICA CAMS (CN) | 2016-07-13 | — | — | EP | disclosed |
| US-8524744-B2 | preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc. | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-09-03 | — | — | US | disclosed |
| US-20080221106-A1 | Arylamine Ketones, Their Preparation Methods, The Pharmaceutical Composition Containing Them And Their Use | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2008-09-11 | — | — | US | disclosed |
| CN-101146772-A | Arylamine ketone compound, synthesis method thereof, pharmaceutical composition containing arylamine ketone compound and application of arylamine ketone compound | INST MATERIA MEDICA CAMS (CN) | 2008-03-19 | — | — | CN | disclosed |
| EP-1783115-A1 | ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | ABCG2 4866/4885NPC1 4100/4885RAB9A 1030/4885 |
| US-20080221106-A1 | Arylamine Ketones, Their Preparation Methods, The Pharmaceutical Composition Containing Them And Their Use | AHR, KYNU, AADAC | ABCG2 1271/4885NPC1 658/4885RAB9A 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.